OTCMKTS:BETRF

BetterLife Pharma Competitors

$0.51
+0.01 (+2.00 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.31
$0.53
50-Day Range
$0.50
$1.10
52-Week Range
$0.25
$2.59
Volume31,427 shs
Average Volume78,268 shs
Market Capitalization$8.78 million
P/E RatioN/A
Dividend YieldN/A
Beta3.8

Competitors

BetterLife Pharma (OTCMKTS:BETRF) Vs. CANF, SOAN, HOTH, PTPI, GNBT, and AMAR

Should you be buying BETRF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BetterLife Pharma, including Can-Fite BioPharma (CANF), AngioSoma (SOAN), Hoth Therapeutics (HOTH), Petros Pharmaceuticals (PTPI), Generex Biotechnology (GNBT), and Amarillo Biosciences (AMAR).

BetterLife Pharma (OTCMKTS:BETRF) and Can-Fite BioPharma (NYSEAMERICAN:CANF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

BetterLife Pharma has a beta of 3.8, suggesting that its share price is 280% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.

Insider & Institutional Ownership

0.6% of Can-Fite BioPharma shares are owned by institutional investors. 34.8% of BetterLife Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares BetterLife Pharma and Can-Fite BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BetterLife PharmaN/A-734.15%-219.66%
Can-Fite BioPharma-1,648.57%-215.41%-120.24%

Analyst Ratings

This is a summary of recent ratings and recommmendations for BetterLife Pharma and Can-Fite BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BetterLife Pharma0000N/A
Can-Fite BioPharma00103.00

Can-Fite BioPharma has a consensus price target of $5.00, indicating a potential upside of 145.10%. Given Can-Fite BioPharma's higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than BetterLife Pharma.

Earnings & Valuation

This table compares BetterLife Pharma and Can-Fite BioPharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BetterLife PharmaN/AN/A$-14,780,000.00N/AN/A
Can-Fite BioPharma$2.03 million17.28$-9,590,000.00($3.30)-0.62

Can-Fite BioPharma has higher revenue and earnings than BetterLife Pharma.

Summary

Can-Fite BioPharma beats BetterLife Pharma on 7 of the 11 factors compared between the two stocks.

AngioSoma (OTCMKTS:SOAN) and BetterLife Pharma (OTCMKTS:BETRF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Valuation and Earnings

This table compares AngioSoma and BetterLife Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AngioSomaN/AN/A$-540,000.00N/AN/A
BetterLife PharmaN/AN/A$-14,780,000.00N/AN/A

Profitability

This table compares AngioSoma and BetterLife Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AngioSomaN/AN/A-612.70%
BetterLife PharmaN/A-734.15%-219.66%

Risk & Volatility

AngioSoma has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, BetterLife Pharma has a beta of 3.8, indicating that its stock price is 280% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for AngioSoma and BetterLife Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AngioSoma0000N/A
BetterLife Pharma0000N/A

Hoth Therapeutics (NASDAQ:HOTH) and BetterLife Pharma (OTCMKTS:BETRF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Volatility and Risk

Hoth Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, BetterLife Pharma has a beta of 3.8, meaning that its share price is 280% more volatile than the S&P 500.

Earnings & Valuation

This table compares Hoth Therapeutics and BetterLife Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hoth TherapeuticsN/AN/A$-7,700,000.00N/AN/A
BetterLife PharmaN/AN/A$-14,780,000.00N/AN/A

Profitability

This table compares Hoth Therapeutics and BetterLife Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hoth TherapeuticsN/A-213.12%-192.10%
BetterLife PharmaN/A-734.15%-219.66%

Analyst Recommendations

This is a breakdown of current ratings for Hoth Therapeutics and BetterLife Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hoth Therapeutics0000N/A
BetterLife Pharma0000N/A

Insider and Institutional Ownership

1.6% of Hoth Therapeutics shares are held by institutional investors. 17.3% of Hoth Therapeutics shares are held by insiders. Comparatively, 34.8% of BetterLife Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Hoth Therapeutics beats BetterLife Pharma on 4 of the 6 factors compared between the two stocks.

BetterLife Pharma (OTCMKTS:BETRF) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Insider and Institutional Ownership

39.6% of Petros Pharmaceuticals shares are held by institutional investors. 34.8% of BetterLife Pharma shares are held by company insiders. Comparatively, 9.7% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BetterLife Pharma and Petros Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BetterLife PharmaN/A-734.15%-219.66%
Petros PharmaceuticalsN/A-46.08%-44.74%

Volatility & Risk

BetterLife Pharma has a beta of 3.8, indicating that its share price is 280% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for BetterLife Pharma and Petros Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BetterLife Pharma0000N/A
Petros Pharmaceuticals0000N/A

Valuation and Earnings

This table compares BetterLife Pharma and Petros Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BetterLife PharmaN/AN/A$-14,780,000.00N/AN/A
Petros PharmaceuticalsN/AN/A$-15,140,000.00N/AN/A

Summary

BetterLife Pharma beats Petros Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

BetterLife Pharma (OTCMKTS:BETRF) and Generex Biotechnology (OTCMKTS:GNBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk and Volatility

BetterLife Pharma has a beta of 3.8, indicating that its stock price is 280% more volatile than the S&P 500. Comparatively, Generex Biotechnology has a beta of -2.64, indicating that its stock price is 364% less volatile than the S&P 500.

Profitability

This table compares BetterLife Pharma and Generex Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BetterLife PharmaN/A-734.15%-219.66%
Generex Biotechnology-1,722.93%-1,712.86%-69.66%

Insider & Institutional Ownership

0.0% of Generex Biotechnology shares are owned by institutional investors. 34.8% of BetterLife Pharma shares are owned by insiders. Comparatively, 35.2% of Generex Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for BetterLife Pharma and Generex Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BetterLife Pharma0000N/A
Generex Biotechnology0000N/A

Earnings & Valuation

This table compares BetterLife Pharma and Generex Biotechnology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BetterLife PharmaN/AN/A$-14,780,000.00N/AN/A
Generex Biotechnology$2.66 million12.11$-33,330,000.00N/AN/A

BetterLife Pharma has higher earnings, but lower revenue than Generex Biotechnology.

Summary

Generex Biotechnology beats BetterLife Pharma on 5 of the 9 factors compared between the two stocks.

BetterLife Pharma (OTCMKTS:BETRF) and Amarillo Biosciences (OTCMKTS:AMAR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk & Volatility

BetterLife Pharma has a beta of 3.8, indicating that its share price is 280% more volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500.

Profitability

This table compares BetterLife Pharma and Amarillo Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BetterLife PharmaN/A-734.15%-219.66%
Amarillo Biosciences-7,434.30%N/A-320.19%

Analyst Recommendations

This is a summary of current ratings and price targets for BetterLife Pharma and Amarillo Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BetterLife Pharma0000N/A
Amarillo Biosciences0000N/A

Earnings & Valuation

This table compares BetterLife Pharma and Amarillo Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BetterLife PharmaN/AN/A$-14,780,000.00N/AN/A
Amarillo Biosciences$10,000.003,218.05$-1,580,000.00N/AN/A

Amarillo Biosciences has higher revenue and earnings than BetterLife Pharma.


BetterLife Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Can-Fite BioPharma logo
CANF
Can-Fite BioPharma
1.4$2.04+2.5%$35.07 million$2.03 million-1.10Analyst Upgrade
News Coverage
AngioSoma logo
SOAN
AngioSoma
1.0$0.07+0.0%$33.71 millionN/A0.00Upcoming Earnings
Gap Down
HOTH
Hoth Therapeutics
0.5$1.48+1.4%$33.71 millionN/A0.00Upcoming Earnings
Gap Down
PTPI
Petros Pharmaceuticals
0.3$3.40+5.3%$33.21 millionN/A-0.89News Coverage
Gap Down
Generex Biotechnology logo
GNBT
Generex Biotechnology
0.7$0.28+3.6%$32.21 million$2.66 million-0.63
AMAR
Amarillo Biosciences
0.5$0.77+27.5%$32.18 million$10,000.000.00Gap Down
RegeneRx Biopharmaceuticals logo
RGRX
RegeneRx Biopharmaceuticals
0.6$0.23+4.3%$31.05 million$80,000.000.00
NovaBay Pharmaceuticals logo
NBY
NovaBay Pharmaceuticals
0.6$0.72+2.8%$30.08 million$6.60 million-1.71Earnings Announcement
News Coverage
Pharmaxis logo
PXSLY
Pharmaxis
0.6$1.00+9.0%$30.00 million$8.75 million0.00
INBP
Integrated BioPharma
1.2$1.00+0.0%$29.77 million$52.77 million9.25Upcoming Earnings
Immuron logo
IMRN
Immuron
0.5$5.24+2.3%$29.77 million$1.69 million0.00
Alterity Therapeutics logo
ATHE
Alterity Therapeutics
0.2$1.31+3.8%$29.61 million$90,000.000.00Gap Down
CPHI
China Pharma
0.8$0.64+1.6%$29.22 million$10.92 million-1.36Gap Up
Artelo Biosciences logo
ARTL
Artelo Biosciences
1.6$1.25+0.0%$28.92 millionN/A-1.24Analyst Downgrade
Akari Therapeutics logo
AKTX
Akari Therapeutics
1.4$1.81+2.8%$28.71 millionN/A-2.45Gap Up
Sonnet BioTherapeutics logo
SONN
Sonnet BioTherapeutics
1.7$1.62+4.3%$28.44 million$30.14 million0.00News Coverage
Gap Up
EyeGate Pharmaceuticals logo
EYEG
EyeGate Pharmaceuticals
1.7$3.93+1.8%$27.90 million$2.69 million-1.96Upcoming Earnings
Gap Up
InMed Pharmaceuticals logo
INM
InMed Pharmaceuticals
1.7$3.45+2.6%$27.78 millionN/A0.00Upcoming Earnings
News Coverage
Gap Up
PRFX
PainReform
1.0$2.73+2.6%$27.47 millionN/A0.00
Bellicum Pharmaceuticals logo
BLCM
Bellicum Pharmaceuticals
1.3$3.30+3.3%$27.45 million$7.14 million-0.25Gap Down
Provectus Biopharmaceuticals logo
PVCT
Provectus Biopharmaceuticals
0.6$0.07+0.0%$27.32 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Up
Midatech Pharma logo
MTP
Midatech Pharma
0.7$2.12+4.7%$26.87 million$860,000.000.00Decrease in Short Interest
Gap Down
Mateon Therapeutics logo
MATN
Mateon Therapeutics
1.5$0.28+0.0%$25.49 millionN/A0.00Gap Up
EMBI
Emerald Bioscience
0.5$0.09+11.1%$24.13 millionN/A-1.13Gap Up
Q BioMed logo
QBIO
Q BioMed
0.5$0.93+1.2%$24.03 millionN/A-1.43
Mallinckrodt logo
MNKKQ
Mallinckrodt
0.8$0.26+7.6%$22.31 million$3.16 billion-0.01Upcoming Earnings
Gap Down
Abliva AB (publ) logo
NEVPF
Abliva AB (publ)
0.5$0.08+25.0%$21.57 million$10,000.00-1.60High Trading Volume
Gap Up
Millendo Therapeutics logo
MLND
Millendo Therapeutics
1.5$1.09+1.8%$20.76 millionN/A-0.45Upcoming Earnings
High Trading Volume
Gap Up
Benitec Biopharma logo
BNTC
Benitec Biopharma
0.6$4.22+1.2%$20.33 million$100,000.00-0.52Increase in Short Interest
SXTC
China SXT Pharmaceuticals
0.4$1.24+0.0%$19.24 million$5.16 million0.00
XTLB
XTL Biopharmaceuticals
0.6$3.40+0.9%$17.48 millionN/A-5.48Gap Up
Bioxytran logo
BIXT
Bioxytran
0.0$0.17+5.9%$17.13 millionN/A0.00Upcoming Earnings
News Coverage
Xenetic Biosciences logo
XBIO
Xenetic Biosciences
1.5$1.86+1.1%$16.27 million$20,000.000.00Upcoming Earnings
Gap Down
Sonoma Pharmaceuticals logo
SNOA
Sonoma Pharmaceuticals
0.5$7.44+3.2%$15.45 million$18.94 million-8.36Gap Down
NRIFF
Nuvo Pharmaceuticals
0.7$1.34+9.0%$15.28 million$52.41 million33.50Gap Down
NVLNF
Novelion Therapeutics
0.6$0.70+1.2%$13.77 million$130.43 million0.00Gap Up
Medicure logo
MCUJF
Medicure
0.6$1.28+3.1%$13.12 million$15.20 million-1.02Upcoming Earnings
News Coverage
Gap Down
Intec Pharma logo
NTEC
Intec Pharma
1.4$3.54+1.7%$12.72 millionN/A-0.50Upcoming Earnings
News Coverage
Gap Up
NMUS
Nemus Bioscience
0.6$0.09+11.1%$12.05 millionN/A0.00High Trading Volume
Gap Up
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08+0.0%$11.99 millionN/A-3.90
Teligent logo
TLGT
Teligent
1.2$0.55+3.7%$11.87 million$65.90 million-0.06Gap Down
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04+26.7%$9.70 million$7.38 million0.00Gap Up
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.18+0.0%$9.70 millionN/A-0.34News Coverage
Gap Down
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.18+0.0%$9.70 millionN/A-0.34News Coverage
Gap Down
Williston logo
WHCA
Williston
0.0$0.70+0.0%$9.51 millionN/A0.00
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.10+0.0%$9.33 million$4.08 million-1.11Gap Up
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.38+5.3%$8.40 million$2.66 million-12.67News Coverage
Gap Down
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.11+0.0%$8.39 millionN/A0.00Gap Up
ULUR
ULURU
0.3$0.28+0.0%$8.17 millionN/A0.00High Trading Volume
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.14+14.7%$7.54 millionN/A0.00Gap Up
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.